Rafoxanide

Research use only, not for human use.

A salicylanilide anthelmintic agent that also shows to be an allosteric inhibitor of SPAK and OSR1.

A salicylanilide anthelmintic agent that also shows to be an allosteric inhibitor of SPAK and OSR1; has antiangiogenic activity in zebrafish with IC50 of 1.69 uM on the intersegmental vessels and 1.45 uM on the subintestinal vessels.Parasite Infection Approved.

Western Blot Analysis Cell Line:HCT-116 Concentration:1.25, 2.5, 5μM Incubation Time:24 h Result:Increased phosphorylate eIF2α and CHOP, which is the hallmark feature of ERS.Apoptosis Analysis Cell Line:HCEC-1CT, HCT-116 and DLD-1 Concentration:1.25, 2.5, 5μM Incubation Time:24, 48, 60 h Result:Detected cell death of HCT-116 and DLD-1 from 48 h while no significant cell death was observed in HCEC-1CT. Pre-incubation of CRC cells with the pan-caspase inhibitor Q-VD-OPH totally reverted the rafoxanide-induced cell death, indicating the involvement of apoptotic pathways.

Animal Model:AOM induced Apcmin/+mice Dosage:7.5 mg/kg Administration:Intraperitoneal injection (i.p.), once every 2 d for 88dResult:Exerted less number and size of AOM induced lesions in the colon. No significant body weight changes were observed. Detected adenomas (28.6%), advanced adenomas (67.8%) and adenocarcinoma (3.6%) in control group as adenomas (33.3%), advanced adenomas (25%%) and no obvious lesions(41.6%) were detected in treated group. Caused increased signal for p-eIF2α, CHOP and cleaved caspase-3 in tumor tissues while these signal in non-tumor colon epithelium were barely detectable.

Rafoxanide | BRN 2228187 | Disalan | Duofas | EINECS 245-148-9

Microbiology/Virology

Parasite

Parasite

Infection

Parasite Infection

22662-39-1

626.0105

C19H11Cl2I2NO3

>98% (HPLC)

DMSO: ≥ 31 mg/mL

C1=CC(=CC=C1OC2=C(C=C(C=C2)NC(=O)C3=C(C(=CC(=C3)I)I)O)Cl)Cl

Benzamide, N-[3-chloro-4-(4-chlorophenoxy)phenyl]-2-hydroxy-3,5-diiodo-

(-20℃)

With Ice Pack

≥ 2 years